InterventionsHumans

Real-World Data Show No Preventive Effect of SGLT2 Inhibitors on Cardiac Dysfunction from Cancer Therapy in T2DM Patients

AHA Scientific Sessions 2025 Abstract

The paper

Kuan Yu Chi, Armin Nouri, Pei‐Lun Lee,

Xaviar Michael Jones, Zafer Akman, Raiza Rossi, Shefa Arya Nezhad, Roberto Lapetina Arroyo, Cesia Gallegos,

Michael G. Nanna

Jacobi Medical Center · Yale University

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4366959

doi.org/10.1161/circ.152.suppl_3.4366959

Drug class linked to fewer deaths or complications in kidney disease
The American Journal of Cardiology · 8 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Pharmacology and Therapeutics · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026